AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04477525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Erector Spinae Plane (ESP) Nerve Block
Description: The planned intervention is a bilateral erector spinae nerve block for patients undergoing bariatric surgery. This intervention will be performed in the PACU for patients with an NRS pain score >5. All eligible candidates who have consented for this study will be present in the PACU, have all standard ASA monitoring placed. The patient will then be placed in a sitting position. The patient will then be prepped with chlorhexidine in the thoracic region and draped in a sterile fashion. The ultrasound will be brought in over the patient and the T7 Transverse Processes (TP) will be identified. An echogenic needle will be placed under direct ultrasound guidance on the TP. Then, 20 cc of 0.25% bupivacaine will be injected.
Study NCT04477525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Injection
Description: 20 cc of 0.25% bupivacaine will be injected
Study NCT06507332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg
Description: to assess and compare the efficacy of Combination of letrozole and clomiphene citrate versus letrozole alone for ovulation induction in women with polycystic ovary syndrome (PCOS)
Study NCT06231641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lemborexant 5 MG [Dayvigo]
Description: Lemborexant 5 mg will be taken orally once per day just prior to initiating laboratory-supervised daytime sleep episodes, for three consecutive days, within a few minutes before going to bed, with at least seven hours remaining before the planned time of awakening.
Study NCT06231641 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo will be taken orally once per day just prior to initiating laboratory-supervised daytime sleep episodes, for three consecutive days, within a few minutes before going to bed, with at least seven hours remaining before the planned time of awakening.
Study NCT04959604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG-marking endoscopically
Description: Preoperatively the participants will receive an endoscopic marking at four points around the tumour with the fluorescent dye indocyanine green.
Study NCT06222567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 15 minutes pumping with INITIATE program
Description: 15 minutes pumping with INITIATE program
Study NCT04753723 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gentamycin with Platform Wound Device
Description: Treatment of wounds with gentamycin and covered with platform wound device.
Study NCT05523804 — intervention group
Intervention type: PROCEDURE
Intervention: interval cytoreductive surgery
Description: cytoreductive surgery after 3-4 cycles of chemotherapy
Study NCT05523804 — intervention group
Intervention type: PROCEDURE
Intervention: delayed cytoreductive surgery
Description: surgery after >5 cycles of chemotherapy
Study NCT05523804 — intervention group
Intervention type: OTHER
Intervention: no surgery
Description: no cytoreductive surgery (>5 cycles of chemotherapy alone)
Study NCT05059847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Training routine assigned by randomized chart
Study NCT05059847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Training routine assigned by randomized chart
Study NCT05381675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-rehabillitation
Description: Tele-rehabilitation program will be performed by physiotherapist two times a week for six consecutive weeks. Program including the following exercises:~Breathing exercises Aerobic exercises Flexibility Strengthening exercises
Study NCT05381675 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prescribed Exercise Program
Description: The prescribed exercise program will be performed two times a week for six consecutive weeks. Program including the following exercises:~Breathing exercises Aerobic exercises Flexibility Strengthening exercises
Study NCT05452824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi Prehabilitation
Description: The intervention arm will be oriented to a WaQi (youthful vitality) program 8 weeks prior to their scheduled surgery date. The WaQi program uses a Tai Chi curriculum previously successfully implemented in older adults, and at the Memorial Sloan Kettering Cancer Center (MSKCC). It has an online teaching module and is uniquely suited for our study population. The program requires no difficult movement transitions, but still contains all essential parts including meditation. The WaQi program has less psychological stress and physical challenge than other exercise activities because it can be performed either sitting or standing. Intervention participants will also receive printed materials from Prostate Cancer Canada about prostate cancer management. These materials include information about how to cope with prostate cancer including pelvic floor exercise, physical activity, healthy eating, and mental wellbeing.
Study NCT05452824 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Control arm participants will receive printed materials identical to intervention arm participants with general information on a healthy lifestyle. The control arm will receive an 8-week online Tai Chi teaching module subscription at the end of the study.
Study NCT05210621 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ocrelizumab
Description: ocrelizumab will be administered as single 600-mg infusions in 500 mL 0.9% sodium chloride every 24 weeks (±14 days) up to Week 192 (Year 4) of this study
Study NCT05152667 — intervention group
Intervention type: DEVICE
Intervention: levonorgestrel-releasing intrauterine device (LNG-IUS)
Description: Intervention is administered proceeding the ICSI
Study NCT04735861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg iv. q3w, up to 2 years.
Study NCT04735861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Biosimilar IBI305
Description: Bevacizumab 15mg/kg iv. q3w, up to 22 cycles
Study NCT04555720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary Visit
Description: If assigned to the interdisciplinary group, participants will see social work, physical therapy, occupational therapy, speech therapy, and pharmacy in a scheduled rotation for about 45 minutes each. After these evaluations, the team meets with the participants doctor for a discussion of treatment. After this meeting, the participants doctor will meet to discuss a treatment plan and make recommendations.
Study NCT06222567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5 minutes extra pumping with MAINTAIN program
Description: Additional 5 minutes extra pumping with MAINTAIN program
Study NCT05254951 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tidal Volume Challenge
Description: Tidal Volume Challenge to predict fluid responsiveness with stroke volume variation and pulse pressure variation
Study NCT06006065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Upper limb somatosensory discrimination therapy
Description: Participants will receive three 45 minute sessions of upper limb somatosensory discrimination therapy per week for a period of 8 weeks.~Each session includes 30 minutes of component-based training, including graded practice of three components of somatosensation (i.e., tactile object recognition, texture discrimination and proprioception). Next, 15 minutes of occupation-based practice will be completed to enhance transfer to a functional context. This includes repetitive and structured practice of self-chosen activities of daily living, while attention is designated to the somatosensory aspects necessary for successful task completion (e.g., identification of button based on touch).
Study NCT06006065 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Upper limb motor therapy
Description: Participants in the control group will receive an equal amount of motor training, including 30 minutes of unimanual motor tasks and 15 minutes of bimanual goal directed training. The unimanual motor tasks will be selected based on the main difficulties of the child (e.g., grip strength, supination). Bimanual goal directed training includes whole task practice of self-chosen activities of daily living. All therapy sessions will be performed under supervision of a trained physical and/or occupational therapist. Therapy adherence and progression will be closely monitored by the therapist.
Study NCT05046873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL
Description: Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.
Study NCT05046873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide 1.34 mg/mL (placebo)
Description: Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.
Study NCT05046873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 1.34 mg/mL
Description: The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
Study NCT06439017 — intervention group
Intervention type: OTHER
Intervention: Questionaire
Description: The study will involve completing the Mind Excessively Wandering Scale (MEWS) and World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0), a 36-item self-administered questionnaire.
Study NCT05753410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Courage
Description: Self-guided online intervention
Study NCT04838275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week mHealth home exercise prescription
Description: 3x/week home walking protocol, 2x/week resistance exercise program
Study NCT05046873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NNC0480-0389 A 10 mg/mL
Description: The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
Study NCT05729555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound ibuprofen polyrelease tablets
Description: Specification: Each tablet containing ibuprofen 400 mg, diphenhydramine hydrochloride 50 mg Batch number: 22082801 Content: Ibuprofen 96.9%, diphenhydramine hydrochloride 102.4% Effective: August 27,2024 S torage conditions: sealed, room temperature. Manufacturers: Overseas Pharmaceuticals, Ltd. Usage and dosage：Once a day, one tablet at a time
Study NCT05729555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reference 1 (R1): Ibuprofen Tablets (Motrin IB®)reference 2 (R2): Diphenhydramine Hydrochloride Tablets (Benadryl®)
Description: Specification: 200 mg Batch number: 2CE2330 Content: 100.5% Expiry date: December 2023 Storage conditions; Storage in 20℃ -25℃ manufacturer: JOHNSON \& JOHNSON CONSUMER INC. Usage and dosage：Once a day, two tablets at a time~Specification: 25 mg Batch number: BCC009 Content: 99.2% Effective to: December 2023 storage conditions; storage at 20℃ -25℃, shading manufacturer: JOHNSON \& JOHNSON CONSUMER INC Usage and dosage：Once a day, two tablets at a time
Study NCT05657938 — intervention group
Intervention type: DEVICE
Intervention: Wearable Device
Description: The wearable device used in this study is an FDA 510(k) cleared Class II medical device designed to collect medical grade, clinical quality biometric, physiological and other electronic clinician outcome assessments data in a clinical trial setting. The system processes raw data into recognizable clinical metrics including vital signs, activity and posture classifications, surface electromyography (sEMG), and sleep metrics. The sensors are multi-modal, multilocation, rechargeable and reusable.
Study NCT05657938 — intervention group
Intervention type: OTHER
Intervention: Duchenne Video Assessment (DVA)
Description: The DVA is a standardized tool that documents and assesses compensatory movement strategies as a marker of quality of movement.
Study NCT06306755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Risk Assessment and Individualized Surveillance
Description: 1. An epidemiological questionnaire-based risk assessment for UGIC conducted prior to the endoscopic examination;~2. Individuals identified as high-risk receive the upper gastrointestinal endoscopic examination with Lugol's Iodine in the esophagus and indigo carmine staining in the stomach;~3. Individualized reexamination and surveillance strategy will be given to participants diagnosed with premalignant lesions, based on evaluation of risk progression using endoscopic characteristics, pathological diagnosis, and biomarkers.
Study NCT06306755 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Universal screening
Description: 1. A questionnaire investigation;~2. All participants undergo the upper gastrointestinal endoscopic examination with Lugol's Iodine in the esophagus and indigo carmine staining in the stomach;~3. Reexamination and surveillance will be performed according to the current guidelines for UGIC screening and clinical treatment.
Study NCT05929079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC
Study NCT05929079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT05613205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TYP04A Low Dose without Alum investigational vaccine
Description: 2 doses of TYP04A Low Dose without Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
Study NCT05613205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TYP04B Full Dose without Alum investigational vaccine
Description: 2 doses of TYP04B Full Dose without Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
Study NCT05613205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TYP03A Low Dose with Alum investigational vaccine
Description: 2 doses of TYP03A Low Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
Study NCT05613205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TYP03B Full Dose with Alum investigational vaccine
Description: 2 doses of TYP03B Full Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
Study NCT05613205 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sanofi Pasteur's Typhoid Vi polysaccharide vaccine
Description: 1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly, at Day 1, to participants in the control group.
Study NCT05613205 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine
Description: 1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine administered intramuscularly, at Day 169, to participants in the control group.
Study NCT04984837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacutamab
Description: 750 mg/IV
Study NCT04984837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m²
Study NCT04984837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m²
Study NCT04984837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatine
Description: 100 mg/m²
Study NCT04984837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatine
Description: 100 mg/m²
Study NCT04832360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Financial incentives may be offered to participants based on their behavioral outcomes (smoking cessation and participation in online psychoeducation about smoking)
Study NCT05944809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: Standard treatment options:~Radiotherapy: 95% planning target volume （planning target volume，PTV） ≥45Gy(without simultaneous boost).~Concurrent chemotherapy:~Weekly regimen: paclitaxel 50mg/m2 d1, nedaplatin/cisplatin 25 mg/m2d1, a total of 5 cycles.~Three weeks regimen: paclitaxel 135-175mg/m2 d1, nedaplatin/cisplatin 80mg/m2, a total of 2 cycles.~The active bone marrow was determined by magnetic resonance（magnetic resonance，MR）, and the dose limits are: V5\<95%,V10\<85%,V20\<60%，V30\<40%；95%PTV>45Gy.~rhTPO，15000U ih. qw(during the radiotherapy course)
Study NCT06026072 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CLAD-V SCORE
Description: the CLAD-V score is measured by the doctor during the emergency take care. After 7 days the patient will be call back to compare the prediction of CLAD-V score and the reality of surgical intervention or no.
Study NCT04737083 — intervention group
Intervention type: GENETIC
Intervention: CGH array
Description: a CGH array is systematically offer to women when the fetus show bilateral clubfoot during prenatal ultrasound screening
Study NCT05085041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Component eHealth Intervention, namely Healthy Online Parental Education (HOPE)
Description: The investigators will provide 8 sessions of a multi-component education intervention to the participants in the intervention group. Each session will address parental nutrition knowledge, self-efficacy, and attitudes around feeding, parental modeling of healthy foods, and skill development to increase success in making behavioral changes. The intervention curriculum will be informed by Social Cognitive Theory to help parents guide young children to engage in healthy eating behaviors through modeling (Curriculum Design). The investigators will deliver the intervention using multicomponent to enhance and maximize the learning experiences of the participants for successful behavior changes. The intervention will be comprised of instructional videos, text messages with key information, online cooking activities, and telephone consultation (Modality).
Study NCT05296551 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor Task
Description: A visuomotor task is presented where an individual must match their knee to an ellipse that moves up and down on a screen, resulting in a marching-in-place motion at a specified frequency.
Study NCT05296551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-motor dual-task
Description: While performing the Motor Task intervention, letters of different colors and orientation randomly appear one at a time on the screen. During the Cognitive-motor dual-task, individuals are instructed to count the number of times that either 1 (simple cognitive task), or 2 (complex cognitive task) characters appear on the screen during the motor task.
Study NCT06158464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Capacity Evaluation
Description: In a FCE, an occupational therapist will evaluate a patient's ability to perform work-related tasks, using a battery of tests. Depending on the circumstances, he/she will for instance test fatigue, ask the patient to kneel, lift objects, or assess concentration. This assessment lasts ± 4 hours and includes physical tests and tests related to the (previous or reference) profession of the client. This means that an explicit match is made between the functional capacities of the patient (what is he/she capable of) and the demands of a certain job (what is he/she expected to do). Following this assessment, the occupational therapist will explain the results of this assessment to the patient. The evaluation will therefore take place during one or two visits.
Study NCT06093542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7053
Description: Randomised participants will receive AZD7503 subcutaneously.
Study NCT06093542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomised participants will receive placebo subcutaneously.
Study NCT05645796 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adopted contrast media amount by using different approaches
Description: Using different contrast media approaches recommended by literature to explore the impact on the contrast enhancement in chest CT
Study NCT04742010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: * A single treatment 21 days before bariatric surgery with Zoledronic acid 5 mg or placebo (an interval of 5 to 180 days is accepted)~* Pharmaceutical form: Solution for infusion (100 ml normal saline containing 5 mg zoledronic acid or placebo)~* Administration: slow intravenous infusion with a duration of at least 15 minutes
Study NCT04742010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: as above
Study NCT06558032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg Sustained Release Tablet (produced by PT Dexa Medica, Indonesia)
Description: One tablet of the test drug was given orally under fasting condition
Study NCT06558032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Harnal® OCAS 0.4 mg Prolonged Release Tablet (produced by Astellas Pharma Europe B.V., The Netherlands, imported by PT Combiphar, Indonesia)
Description: One tablet of the test drug was given orally under fasting condition